India Pharma Outlook Team | Tuesday, 14 October 2025
Eli Lilly today announced it will present clinical data on Verzenio and multiple novel pipeline updates at the ESMO 2025 Annual Meeting in Berlin from October 17-21.
The new data includes updates from across Lilly’s oncology portfolio as part of Lilly’s commitment to advancing cancer treatment across tumour types and modalities.
During a late-breaking oral session, Lilly will present the seven-year follow-up of the important monarchE study, including the primary overall survival analysis and updates on invasive disease-free survival and distant relapse-free survival from patients receiving treatment for HR+, HER2- early breast cancer at high risk. There will also be an additional mini-oral session with superset and predictive analysis of Ki-67 index before and after neoadjuvant chemotherapy.
Also Read: India's Innovative Therapies Set Global Standard at Low Cost
Additionally, Lilly's pipeline-related activity is causing a spotlight on Olomorasib (LY3537982), a next-generation KRAS G12C inhibitor. Lilly is showing efficacy and will report efficacy in a mini-oral presentation, focusing on intracranial efficacy in patients with untreated brain metastases from KRAS G12C-mutant NSCLC.
Meanwhile, LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor, will have a late-breaking oral presentation of its updated data in patients with PIK3CA-mutant advanced breast cancer and other solid tumours. Vepugratinib (LY3866288) will present its first-in-human data in patients with FGFR3-altered urothelial cancer and LY4187156, an ADC directed against folate receptor α, will present evidence of safety and efficacy in patients with platinum-resistant ovarian cancer.
With these data, Lilly aims to continue to build momentum in oncology, expedite development of late-stage clinical data, and drive Verzenio clinical data and next-generation therapies towards regulatory milestones.
